Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474

Development of an Immunohistochemical Protein Quantification System in Conjunction with Tissue Microarray Technology for Identifying Predictive Biomarkers for Phosphatidylinositol 3-Kinase Inhibitors

(2015) Sho Isoyama et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance

(2012) Sho Isoyama et al.   CANCER SCIENCE

Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2

(2012) K. D. Copps et al.   DIABETOLOGIA

Circumventing Cancer Drug Resistance in the Era of Personalized Medicine

(2012) Levi A. Garraway et al.   Cancer Discovery

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors

(2011) S. J. Shuttleworth et al.   CURRENT MEDICINAL CHEMISTRY

Predictive biomarkers: a paradigm shift towards personalized cancer medicine

(2011) Nicholas B. La Thangue et al.   Nature Reviews Clinical Oncology

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

(2011) A. Chakrabarty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

US FDA perspective on challenges in co-developingin vitrocompanion diagnostics and targeted cancer therapeutics

(2011) Reena Philip et al.   Bioanalysis

Defining the pathway to insulin-like growth factor system targeting in cancer

(2010) Steven A. Rosenzweig et al.   BIOCHEMICAL PHARMACOLOGY

Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status:In silicoand Biological Evaluations

(2010) Shingo Dan et al.   CANCER RESEARCH

Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy

(2010) Deepali Sachdev   CURRENT DRUG TARGETS

The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer

(2010) Cesare Gridelli et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The proliferating role of insulin and insulin-like growth factors in cancer

(2010) Emily Jane Gallagher et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Implications of insulin-like growth factor-I for prostate cancer therapies

(2008) Satoko Kojima et al.   INTERNATIONAL JOURNAL OF UROLOGY

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE